DEF: GT Biopharma Seeks Shareholder Approval for Significant Dilution and Equity Plan Expansion Amidst Mounting Losses

GT Biopharma, Inc. is calling its stockholders to an Annual Meeting on July 24, 2025, to vote on critical proposals including the election of directors, ratification of auditors, an advisory vote on executive compensation, and, most notably, the approval of substantial share issuances and an expansion of its equity incentive plan.

Summary

• The Annual Meeting of Stockholders for GT Biopharma, Inc. is scheduled for July 24, 2025, in Los Angeles, California.
• Stockholders will vote on the election of four directors to serve until the 2026 annual meeting.
• A proposal to ratify Weinberg & Company, P.A. as the independent accountants for the fiscal year ending December 31, 2025, will be presented.
• An advisory vote on executive compensation is on the agenda.
• Stockholder approval is sought for the issuance of 19.99% or more of the company's outstanding Common Stock related to a Securities Purchase Agreement and a Common Shares Purchase Agreement, which could lead to investors holding 51% of voting power and 71% beneficial ownership.
• Approval is also requested for Amendment No. 1 to the 2022 Omnibus Incentive Plan, increasing shares available for future awards by 583,334 to a total of 750,000 shares, representing a potential 23.8% overhang.
• The company reported a net loss of $13,162,000 for the fiscal year ended December 31, 2024, an increase from $7,597,000 in 2023.
• A $100 investment in the company's Common Stock on the last trading day of 2021 was valued at $3.25 by the end of 2024, indicating a significant decline in total shareholder return.
• Executive compensation for the PEO (Michael Breen) decreased from $1,525,834 in 2023 to $1,186,972 in 2024, while average compensation for other NEOs decreased from $1,129,671 in 2023 to $377,782 in 2024.

Sentiment

Score: 2

Explanation: The sentiment is largely negative due to significant financial losses, drastic decline in shareholder value, and the necessity for highly dilutive capital raises. While the company is taking steps to secure funding and incentivize employees, the underlying financial performance and the extent of potential dilution are concerning.

Positives

• The Board of Directors unanimously recommends voting FOR all proposals, including the election of directors, auditor ratification, executive compensation endorsement, the issuance proposal, and the plan amendment proposal.
• The company has adopted a Board Diversity Policy and an Insider Trading Policy to enhance corporate governance.
• The company has engaged an external compensation consultant, Pearl Meyer & Partners, LLC, to advise on board compensation matters, indicating a commitment to informed compensation practices.

Negatives

• The company's net loss significantly increased to $13,162,000 in fiscal year 2024 from $7,597,000 in fiscal year 2023.
• The cumulative total stockholder return shows a drastic decline, with a $100 investment in 2021 reducing to $3.25 by the end of 2024.
• The proposed share issuances under Proposal No. 4 could result in significant dilution, with investors potentially holding 51% of voting power and 71% of beneficial ownership.
• The proposed increase in shares for the 2022 Omnibus Incentive Plan (Proposal No. 5) represents a potential overhang of 23.8% of outstanding shares, further contributing to dilution.

Risks

• Failure to obtain stockholder approval for Proposal No. 4 (Issuance Proposal) will prevent investors from converting Series L Preferred Stock or exercising Warrants in excess of the Beneficial Ownership Limitation or Exchange Cap.
• If Proposal No. 4 is not approved, the company will be required to call a meeting every four months thereafter to seek stockholder approval until approval is obtained or the Preferred Stock is no longer outstanding.

Future Outlook

The company intends to continue utilizing equity awards to attract, retain, and motivate key individuals, aligning their interests with stockholders for long-term growth and financial success. The additional shares requested for the 2022 Plan are projected to be adequate for grants and awards for approximately three years. The company also plans to file resale registration statements for shares issuable under the Securities Purchase Agreement and Common Shares Purchase Agreement to facilitate public resale.

Management Comments

• "Our Board of Directors does not intend to bring any other matters to be voted on at the Annual Meeting, and we are not currently aware of any matters that may be properly presented by others for action at the Annual Meeting."
• "We believe compliance with the SECs notice and access rules allows us to provide our stockholders with the materials they need to make informed decisions, while lowering the costs of printing and delivering those materials and reducing the environmental impact of our Annual Meeting."
• "Our Board determined that the transactions contemplated by each of the Securities Purchase Agreement and the Common Shares Purchase Agreement, and the issuance of the securities thereunder were in the best interests of our Company and its stockholders."
• "Our Board believes that the increase in shares of Common Stock available under the 2022 Plan represents a reasonable amount of potential equity dilution, which will allow us to continue awarding equity incentives, an important component of our overall compensation program."
• "The Board believes that, to attract, motivate, and retain qualified officers, directors, and employees of the Company, to incentivize such persons to attain our long-term goal of increasing stockholder value, and to continue to promote the Companys well-being, it is in the best interests of us and our stockholders to provide our officers, directors, and employees, through the granting of equity incentive awards, the opportunity to participate in the appreciation in value, if any, of our Common Stock."

Industry Context

The biotech industry is highly capital-intensive, often requiring significant funding for research, development, and clinical trials. Companies frequently rely on equity financing, including private placements and committed equity facilities, to fund operations. The proposed capital raises and equity plan expansion by GT Biopharma reflect a common strategy in the sector to secure necessary funding and incentivize talent, especially for companies in the development phase. However, the substantial dilution and declining shareholder return highlight the inherent risks and challenges in bringing biopharmaceutical products to market.

Comparison to Industry Standards

• The significant increase in net loss from $7.597 million in 2023 to $13.162 million in 2024, coupled with a drastic decline in Total Shareholder Return (TSR) from $100 to $3.25 over three years, indicates performance significantly below typical industry benchmarks for a healthy, growing biotech company. While early-stage biotech companies often incur losses, the magnitude of TSR decline suggests severe value destruction.
• The proposed dilution of up to 71% beneficial ownership for new investors and a 23.8% potential overhang from the incentive plan are substantial, even for the biotech sector, which is accustomed to dilution for funding. This level of dilution could be considered aggressive compared to companies with more advanced pipelines or clearer paths to profitability.
• The reliance on convertible preferred stock and warrants, along with a committed equity facility at 93% of VWAP, suggests a need for capital that may not be readily available through less dilutive means, potentially indicating a challenging financial position compared to more established or well-funded peers in the biopharma space.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a Master Services Agreement with Cytovance Biologics, Inc. (Cytovance) since October 2020 for biologic development and manufacturing services.
• A Settlement and Investment Agreement with Cytovance on August 24, 2022, allowed for future invoices to be settled in a combination of cash and issuance of the company's Common Stock, and set Cytovance's beneficial ownership limitation at 4.9%.
• An amendment on April 25, 2024, increased Cytovance's beneficial ownership limitation to 9.9%.
• Cytovance became a related party on June 30, 2024, as its beneficial ownership exceeded 5% of the company's outstanding shares.
• Research and development expenses recognized with Cytovance were $2,335,000 in 2024 and $4,584,000 in 2023.
• Cash payments to Cytovance amounted to $3,857,000 in 2024 and $2,213,000 in 2023.
• The company issued 127,597 shares of Common Stock (valued at approximately $810,000) to Cytovance in 2024 and 57,437 shares (valued at approximately $1,120,000) in 2023 to settle accounts payable.
• As of December 31, 2024, accounts payable to Cytovance amounted to $1,183,000, down from $3,515,000 as of December 31, 2023.
• Commitments in relation to unbilled and unaccrued SOWs and related Change Orders from Cytovance amounted to approximately $1.1 million as of December 31, 2024.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the proposed share issuances (Proposal No. 4) and the expansion of the equity incentive plan (Proposal No. 5), which could substantially reduce their ownership percentage and per-share value. The historical decline in Total Shareholder Return indicates poor past performance for existing shareholders.
• **Employees/Executives**: The expansion of the 2022 Omnibus Incentive Plan aims to attract, retain, and motivate key individuals through equity awards, aligning their interests with long-term company success. Executive compensation, while decreasing for the PEO in 2024, remains substantial.
• **Creditors/Investors (Private Placement & Facility Investors)**: The proposed capital raises via Series L Preferred Stock, Warrants, and a committed equity facility provide crucial funding for the company's operations. These investors stand to gain significant beneficial ownership and voting power if Proposal No. 4 is approved.
• **Suppliers (e.g., Cytovance Biologics)**: Cytovance, a key service provider, has become a related party and has received payments in both cash and company stock, indicating a continued operational relationship and financial reliance.

Next Steps

• Stockholders to vote on proposals at the Annual Meeting on July 24, 2025.
• Company to announce preliminary voting results at the Annual Meeting and report final results on a Current Report on Form 8-K.
• If Proposal No. 4 is not approved, the company will be required to call a meeting every four months thereafter to seek stockholder approval until it is obtained or the Preferred Stock is no longer outstanding.
• Company to file a resale registration statement for Common Stock issuable upon conversion of Series L Preferred Stock and exercise of Warrants within 30 calendar days after May 12, 2025, and after each Greenshoe Right exercise.
• Company to file a resale registration statement for shares issuable under the Common Shares Purchase Agreement within 20 trading days after May 14, 2025.

Key Dates

Recommendation

Keywords

Proxy Statement, SEC Filing, Shareholder Meeting, Corporate Governance, Executive Compensation, Equity Incentive Plan, Stock Dilution, Capital Raise, Preferred Stock, Warrants, Nasdaq Listing Rules, Biopharma, Financial Performance, Net Loss, Total Shareholder Return